FDA Grants Its First Approval for Mesenchymal Cell Therapy in GVHD

The FDA approved remestemcel-L-rknd (Ryoncil, Mesoblast Ltd), the first mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease. This treatment will be available for children aged 2 months and older.

This represents the mesenchymal stromal cell field's first FDA approval for any disease.

What Is GVHD?

Graft-versus-host disease (GVHD) is a complication after allogeneic bone marrow or stem cell transplantation in which donor cells recognize the recipient's tissues as "foreign" and attack them through the immune system. It commonly affects organs such as the skin, liver, and intestines and can cause inflammation and serious damage.

What Is Mesenchymal Stromal Cell Therapy?

Mesenchymal stromal cell (MSC) therapy is a biological treatment that uses specialized cells, usually obtained from sources such as bone marrow or adipose tissue, to heal damaged tissues and regulate immune responses. Through their immunosuppressive and anti-inflammatory properties, these cells offer promise, particularly for immune-related diseases. MSC therapy stands out as a next-generation option for life-threatening conditions such as acute graft-versus-host disease (GVHD).

Ryoncil is a therapeutic product containing allogeneic MSCs obtained from healthy donors' bone marrow. During manufacturing, MSCs isolated from donor bone marrow are cultured and expanded in a laboratory, then frozen and stored by cryopreservation.

GVHD and the Need for a Solution

Each year in the United States, approximately 10,000 people undergo allogeneic bone marrow transplantation , including approximately 1500 children.

Bone marrow transplantation has increased markedly in Turkey in recent years. Approximately 6000 bone marrow transplants are performed annually. About 1000 of these transplants are performed in children. In addition, the number of stem cell transplant centers in Turkey has exceeded 100. These figures show that Turkey ranks among the leading European countries for bone marrow transplantation.

Half of children after transplantation develop steroid-refractory acute graft-versus-host disease (SR-aGVHD), and nearly half of this group do not respond to steroid treatment. SR-aGVHD is a life-threatening condition with a poor prognosis, particularly in children.

In this context, Ryoncil is a groundbreaking treatment option and an important source of hope for children and their families.

Clinical Studies and Efficacy Data

Ryoncil's safety and efficacy were evaluated in a multicenter, single-arm phase 3 study involving 54 children. Most children in the study (89%) had severe Grade C or D disease.

• Day 28 Results:
  • Complete response rate: 30% (16 children)
  • Partial response rate: 41% (22 children)

Treatment responses and their duration were assessed using the International Blood and Bone Marrow Transplant Registry (IBMTR) Severity Index Criteria , which evaluate disease severity. Detailed results were published in Biology of Blood and Marrow Transplantation .

Adverse Effects and Safety Precautions

The most common adverse effects during Ryoncil treatment are:

• Infections
• Fever
• Bleeding
• Edema
• Abdominal pain
• Hypertension

The FDA recommends careful monitoring of infusions during treatment and stopping treatment if signs of an allergic reaction occur. Potential complications include:

• Hypersensitivity and acute infusion reactions
• Risk of infection transmission
• Ectopic tissue formation .

Ryoncil is contraindicated in patients with a known allergy to dimethyl sulfoxide (DMSO) or porcine and bovine proteins. Premedication with corticosteroids and antihistamines is recommended, and patients must be closely monitored for allergic reactions during treatment.

Orphan Drug Status and Distribution

Ryoncil had orphan drug, fast track , and priority review designations and will be available after approval at transplant centers and other treatment-providing hospitals in the United States.

Conclusion: New Hope for Children

Ryoncil's FDA approval is a milestone not only for treating steroid-refractory aGVHD, but also for the future of cell-based therapies. Its potential to save children's lives and the hope it gives families once again highlight the importance of innovative therapies in healthcare.